Valuation: SpringWorks Therapeutics, Inc.

Market Cap 354.06Cr 310.44Cr 286.16Cr 267.9Cr 502.36Cr 33TCr 512.79Cr 3.44TCr 1.33TCr 17TCr 1.33TCr 1.3TCr 57TCr P/E 2023
-7.09x
P/E 2024 -10.4x
Enterprise Value 308.66Cr 270.64Cr 249.47Cr 233.55Cr 437.95Cr 29TCr 447.04Cr 3TCr 1.16TCr 14TCr 1.16TCr 1.13TCr 50TCr EV / Sales 2023
36,25,07,725x
EV / Sales 2024 1,16,54,155x
Free-Float
97.93%
Yield 2023 *
-
Yield 2024 -
1 year 46.98
Extreme 46.98
47.01
3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
89.75
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/01/2023
Compliance Officer - 01/01/2022
Investor Relations Contact - 01/08/2018
Date Insider Type Main position Quantity % Market Cap.
01/25/01Issuer sale

General Counsel

3,97,427 0.5304%
01/25/01Issuer sale

Chief Technology Officer

3,69,000 0.4924%
01/25/01Issuer sale

Director

85,011 0.1134%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%-.--%+92.66% 354.06Cr
+2.06%+3.76%+21.48%-19.31% 6.31TCr
+0.74%+3.52%+53.14%+219.37% 5.56TCr
-3.10%+34.30%+34.30%+34.30% 4.16TCr
-2.36%-1.25%-52.13%-58.98% 3.9TCr
+6.97%+9.89%+70.21%-23.28% 2.98TCr
+12.59%+5.18%+144.26%-44.13% 2.37TCr
+5.78%+15.81%+60.64%+80.73% 2.15TCr
-1.25%-1.31%-4.39%+142.42% 1.69TCr
-0.81%+5.91%+67.70%+124.13% 1.67TCr
Average +2.06%+5.11%+39.52%+54.79% 3.11TCr
Weighted average by Cap. +1.75%+5.35%+37.18%+47.88%

Financials

2023 2024
Net sales 5.45 4.78 4.4 4.12 7.73 513.83 7.89 52.91 20.47 253.95 20.45 20.01 880.57 191.59 167.99 154.84 144.97 271.83 18.07T 277.48 1.86T 720.14 8.93T 719.42 703.71 30.97T
Net income -33Cr -29Cr -26Cr -25Cr -46Cr -3.07TCr -47Cr -315.81Cr -122.2Cr -1.52TCr -122.08Cr -119.41Cr -5.26TCr -26Cr -23Cr -21Cr -20Cr -37Cr -2.44TCr -37Cr -250.75Cr -97Cr -1.2TCr -97Cr -95Cr -4.17TCr
Net Debt -66Cr -57Cr -53Cr -50Cr -93Cr -6.18TCr -95Cr -636.79Cr -246.4Cr -3.06TCr -246.15Cr -240.78Cr -11TCr -45Cr -40Cr -37Cr -34Cr -64Cr -4.28TCr -66Cr -441.02Cr -170.65Cr -2.12TCr -170.48Cr -166.76Cr -7.34TCr
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SWTX Stock